This finding implies that in a clinical setting, the use of dipeptidyl peptidase IV inhibitors to control blood sugar levels should be avoided in diabetic patients at risk for ICC due to the DPP4 potentially promoting the occurrence of ICC. This evidence concerns the gene DPP4 and intrahepatic cholangiocarcinoma.